Cytosorbents (NASDAQ:CTSO – Get Free Report) and Sintx Technologies (NASDAQ:SINT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Valuation & Earnings
This table compares Cytosorbents and Sintx Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytosorbents | $37.06 million | 10.76 | -$8.20 million | ($0.29) | -21.83 |
| Sintx Technologies | $1.08 million | 7.24 | -$10.36 million | ($4.91) | -0.37 |
Profitability
This table compares Cytosorbents and Sintx Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytosorbents | -48.94% | -431.65% | -41.94% |
| Sintx Technologies | -848.20% | -354.44% | -115.37% |
Analyst Ratings
This is a summary of recent ratings and target prices for Cytosorbents and Sintx Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytosorbents | 1 | 1 | 1 | 0 | 2.00 |
| Sintx Technologies | 1 | 0 | 3 | 0 | 2.50 |
Cytosorbents presently has a consensus target price of $107.50, indicating a potential upside of 1,598.26%. Sintx Technologies has a consensus target price of $9.33, indicating a potential upside of 412.82%. Given Cytosorbents’ higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than Sintx Technologies.
Institutional & Insider Ownership
32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Cytosorbents beats Sintx Technologies on 9 of the 13 factors compared between the two stocks.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
About Sintx Technologies
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
